136 related articles for article (PubMed ID: 36446233)
1. Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis.
Tang G; Pan L; Wang Z; Zhu H; Yang Y; Wang Z; Yue H; Shi Y; Wu D; Jiang Z; Jiang D
Int Immunopharmacol; 2023 Jan; 114():109450. PubMed ID: 36446233
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
4. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
[TBL] [Abstract][Full Text] [Related]
6. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
[TBL] [Abstract][Full Text] [Related]
7. CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.
Wu Y; Wang Y; Qin F; Wang Z; Wang Y; Yang Y; Zheng H; Wang Y
Am J Physiol Gastrointest Liver Physiol; 2014 Jun; 306(12):G1056-64. PubMed ID: 24763553
[TBL] [Abstract][Full Text] [Related]
8. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
9. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
[TBL] [Abstract][Full Text] [Related]
10. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
11. HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.
Cui W; Zhao Y; Shan C; Kong G; Hu N; Zhang Y; Zhang S; Zhang W; Zhang Y; Zhang X; Ye L
FEBS Lett; 2012 Mar; 586(6):766-71. PubMed ID: 22293503
[TBL] [Abstract][Full Text] [Related]
12. The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus.
Li L; Cong B; Yu X; Deng S; Liu M; Wang Y; Wang W; Gao M; Xu Y
Arch Oral Biol; 2021 Apr; 124():105064. PubMed ID: 33529836
[TBL] [Abstract][Full Text] [Related]
13. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.
Shang Y; Chai N; Gu Y; Ding L; Yang Y; Zhou J; Ren G; Hao X; Fan D; Wu K; Nie Y
Arch Pathol Lab Med; 2014 Jul; 138(7):910-9. PubMed ID: 24978917
[TBL] [Abstract][Full Text] [Related]
14. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer.
Montalvo-Castro RE; Salinas-Jazmín N
Gac Med Mex; 2022; 158(3):141-149. PubMed ID: 35894744
[TBL] [Abstract][Full Text] [Related]
16. Expression and modulation of RPE cell membrane complement regulatory proteins.
Yang P; Tyrrell J; Han I; Jaffe GJ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3473-81. PubMed ID: 19168900
[TBL] [Abstract][Full Text] [Related]
17. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
[TBL] [Abstract][Full Text] [Related]
19. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
[TBL] [Abstract][Full Text] [Related]
20. The role of membrane complement regulatory proteins in cancer immunotherapy.
Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
